Full Press Release Details
Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference
NEW YORK, Nov. 12, 2021 - Immunovant, Inc. (Nasdaq IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the Stifel 2021 Virtual Healthcare Conference, taking place November 15-17, 2021.
Stifel 2021 Virtual Healthcare Conference Presentation
Date Wednesday, November 17th, 2021
Time 2 00pm Eastern Time
Webcast The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company's website, located at www.immunovant.com
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401 (batoclimab), a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Director, Investor Relations Strategy